[{"id":"e9e77af0-89f1-42d4-a03f-cc0813b452ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT06027086","created_at":"2023-09-07T16:09:42.798Z","updated_at":"2025-02-25T13:41:42.827Z","phase":"Phase 1/2","brief_title":"DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)","source_id_and_acronym":"NCT06027086","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" DNAJB1 • PRKACA","pipe":" | ","alterations":" DNAJB1-PRKACA fusion","tags":["DNAJB1 • PRKACA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DNAJB1-PRKACA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • sirpiglenastat (DRP-104)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 02/12/2024","start_date":" 02/12/2024","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2033","study_completion_date":" 09/01/2033","last_update_posted":"2025-02-21"},{"id":"208e94c5-11e1-4e2c-881a-18ba9d9acb7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06620302","created_at":"2025-02-25T15:15:08.184Z","updated_at":"2025-02-25T15:15:08.184Z","phase":"Phase 1/2","brief_title":"Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma","source_id_and_acronym":"NCT06620302","lead_sponsor":"Children's Oncology Group","biomarkers":" BCL2 • DNAJB1 • PRKACA","pipe":"","alterations":" ","tags":["BCL2 • DNAJB1 • PRKACA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • DT2216"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 03/20/2025","start_date":" 03/20/2025","primary_txt":" Primary completion: 12/30/2031","primary_completion_date":" 12/30/2031","study_txt":" Completion: 12/30/2031","study_completion_date":" 12/30/2031","last_update_posted":"2025-02-13"},{"id":"184b42cd-fc1a-41ec-835c-53a5e57b12cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04248569","created_at":"2021-01-18T20:38:55.389Z","updated_at":"2025-02-25T14:29:00.465Z","phase":"Phase 1","brief_title":"DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma","source_id_and_acronym":"NCT04248569","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8 • CD4 • DNAJB1 • PRKACA","pipe":" | ","alterations":" DNAJB1-PRKACA fusion","tags":["CD8 • CD4 • DNAJB1 • PRKACA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DNAJB1-PRKACA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • DNAJB1-PRKACA peptide vaccine • Hiltonol (poly-ICLC)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 04/20/2020","start_date":" 04/20/2020","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-06-07"},{"id":"0fa8d48e-d40b-4172-a31d-5c264cf991f4","acronym":"FusionVAC22","url":"https://clinicaltrials.gov/study/NCT05937295","created_at":"2023-07-10T13:08:43.081Z","updated_at":"2024-07-02T16:35:35.247Z","phase":"Phase 1","brief_title":"FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition","source_id_and_acronym":"NCT05937295 - FusionVAC22","lead_sponsor":"University Hospital Tuebingen","biomarkers":" DNAJB1 • PRKACA","pipe":" | ","alterations":" DNAJB1-PRKACA fusion","tags":["DNAJB1 • PRKACA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DNAJB1-PRKACA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • DNAJB1-PRKACA peptide vaccine • Fusion-VAC-XS15"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/26/2023","start_date":" 09/26/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-09-29"}]